Just 10 days of bed rest reduces mitochondrial content by double digits in older adults while ROS production spikes. Function stays intact only because each mitochondrion works overtime. A Journal of Physiology study tracked what happens to muscle mitochondria in 10 older men (average age 68) during 10 days of complete bed rest. This simulates what happens during hospitalization, illness recovery, or any period where you stop moving. The findings show a temporary compensation that masks underlying damage. Key findings: • Mitochondrial quantity dropped significantly • Damaging free radical production increased 62-65% • Energy production capacity remained normal • Each remaining mitochondrion worked harder to compensate • Over 3,000 genes changed, with energy pathways shutting down • Antioxidant defenses weakened while stress signals activated After just 10 days of complete inactivity, older adults lost a substantial portion of their mitochondrial mass. Mitochondrial volume density measured by electron microscopy dropped significantly, and citrate synthase activity fell in parallel. But here's the twist: total energy production stayed normal because the remaining mitochondria cranked up their individual output. This sounds like good news. It's not. The compensation comes at a cost. The mitochondria that survived started producing more reactive oxygen species, essentially damaging molecules that your cells normally neutralize with antioxidant systems. Production went up while the cleanup systems got weaker. When damage production outpaces your ability to clear it, problems accumulate. The gene expression data revealed what's happening. More than 3,000 genes changed their activity levels. Genes responsible for building new mitochondria and maintaining energy production all got dialed down. Meanwhile, emergency stress response genes activated. Your muscle is essentially preparing for prolonged shutdown while trying to manage rising damage. This pattern matters because it defines the sequence. Mitochondrial loss and oxidative damage happen first, within 10 days. Actual energy production failure comes later, after the compensation exhausts itself. Previous studies in young adults showed they maintained their mitochondrial content after 10 days of bed rest. Older adults in this study lost it. The age-related difference in resilience to inactivity is significant. Younger muscle can weather short periods of inactivity without shedding mitochondria. Older muscle starts losing them within days. The practical implication: if you're over 65 and face a period of reduced activity from illness, injury, or hospitalization, mitochondrial decline starts almost immediately. The energy production numbers might look fine initially, but you're operating on fewer, overworked mitochondria producing more cellular damage. Once you lose mitochondria, rebuilding them takes time and may be incomplete. This explains why older adults often struggle to return to baseline function after hospitalization or illness. The visible problem is muscle weakness. The underlying driver is mitochondrial loss that happened in the first week or two of inactivity. The intervention window is narrow. Maintaining some level of activity during periods that would otherwise be sedentary, protecting mitochondrial mass before it drops, matters more than trying to rebuild after the fact. For healthy aging, the message is clear: consistency matters more as you age. Younger muscle tolerates gaps in activity. Older muscle doesn't have that buffer. A week or two of complete inactivity triggers changes that weeks or months of training built. The decisions made during short periods of forced inactivity, whether you do simple resistance exercises in bed, walk as soon as possible, or stay completely sedentary, shape the mitochondrial foundation available when you try to resume normal activity. Older muscle operates with less margin for error. The first 10 days of inactivity look deceptively manageable because energy production stays normal. The damage is happening at a level you can't feel yet.

Four weeks of wall squats reduced systolic blood pressure by nearly 10 points in adults with high blood pressure. Researchers then compared continuing three sessions weekly with reducing to two, one, or none for another month. Systolic pressure remained roughly 7 mmHg below starting levels in the once- and twice-weekly groups. Continuing three sessions weekly produced the greatest reduction of about 14 mmHg. In those who stopped completely, blood pressure moved back toward baseline. This fits with a previous analysis of randomized trials that identified isometric exercise, which involves holding a muscle contraction, as an effective way to lower resting blood pressure. What interests me is the practical question - how much of an exercise benefit can we preserve when we temporarily have less time? This study suggests that reducing the frequency can retain part of the benefit for up to a month.

Patient: How fast will high-dose statin treatment regress my 70% stenosis? Doctor: umm… FLOWPROMOTE shed light on this, but before the “how fast”, let’s go over the “how” 1️⃣ Intensive statin therapy lowers circulating LDL, so less crosses into the wall to feed the plaque’s core. 2️⃣ Downregulates endothelial VCAM and ICAM, reducing monocyte recruitment. 3️⃣ Silences macrophages, releasing less VEGF for angiogenesis and intra-plaque hemorrhage. 4️⃣ Silenced macrophages release less MMP-9, so they stop chewing the plaque’s fibrous cap. 5️⃣ Stimulates smooth muscle cells to migrate in and lay down fresh collagen, rebuilding the cap. 6️⃣ Upregulates CCR7, letting lipid-laden foam cells leave the plaque and emigrate to lymph nodes. 7️⃣ Promotes calcification of residual plaque, making it denser and mechanically tougher. 8️⃣ Lowers tissue factor and calms platelets, so if a cap ever ruptures, the clot is smaller and more likely to lyse. Regression is real: with IVUS changes in atheroma volume translating to roughly 1% diameter improvement per year, about 10% over a decade in a best-case scenario. But it can also be invisible, because a vessel often remodels inward as plaque shrinks. And it can be irrelevant, because a plaque that doesn’t rupture doesn’t need to disappear.

7️⃣ things I appreciate about this figure 1. Illustrating HR and 95% CI with forest plot 2. Color coding high risk 🍎 to low risk 🍏 3. Sorting from strongest to weakest effect 4. Including raw event rates and % on right 5. Rounding to the nearest % (🚫4.359%) 6. No cryptic abbreviations 7. High data density without visual clutter 👏 @JACCJournals @TIMIStudyGroup

I’ve observed this in clinic more & more: add a GLP-1RA 💉 … remove an anti-HTN 💊

冠動脈疾患に対する心リハ：コクランのアップデート2026（パイプライン研究.2025NEJMを含むメタ解析） ・心リハは冠動脈疾患患者の全死亡（RR 0.86）、心筋梗塞（RR 0.72）、全入院（RR 0.65）のリスク低下に加え、QOL改善と良好な費用対効果。 Exercise‐based cardiac rehabilitation for coronary heart disease - Dibben, G - 2026 | Cochrane Library cochranelibrary.com/cdsr/doi…

The most important briefings of the day. Karl Deisseroth, professor of bioengineering and of psychiatry and behavioral sciences, shares the news of his Nobel Prize with his kids.

Spoiler alert 👵🏻➡️👧🏻

The phase 3 clinical trials table of AgingBiotech.info (top trials DB of AgingBiotech.info/trials) now updated thanks to work by @tliu44. - New approvals (eg Scholar Rock). - Failed ph3s marked as such. - Prev Ph2 programs now in ph3 added. The pipeline progresses (slowly).

In our lecture series on aging, @FrailtyMD said something very instructive (paraphrasing here): "We have to make an extra effort to distinguish between frailty and multi-morbidity, otherwise, we won't be able to intervene early!" Majority of the deficit accumulation models, e-Frailty, ICD-based frailty indices, etc, measure cumulative comorbidity not frailty. Jon's imaging-based coreslicer (coreslicer.com) is very impressive!! @MichaelGNanna @heartwiselab #innovation

😅 I found a frailty shout-out at the end of the recently published PAD guidelines “endovascular (revascularization) options often suffice for less complex disease and are an option for frail patients also with complex lesions when surgery is unsuitable” Agree/Disagree? How often does frailty tip the scale when deciding on revascularization strategy? @AeroMD

😕

A pragmatic trial is not a fig leaf for sloppy methods with stale EHR data. The #PRECIS2 framework reminds us that effectiveness studies need intentional design, not just convenient shortcuts.

Epidemiological and Mendelian randomization studies consistently show an inverse relationship between adult height and cardiovascular disease — why? 1⃣ Genetics: height-associated SNPs overlap with pathways controlling lipids and BP 2⃣ Development: height is a marker of childhood stress (IUGR, nutrition, repeated infections, low SES) which alter organ development and endothelial function 3⃣ Artery size: smaller coronary and peripheral artery diameters so it takes less plaque to cause critical stenosis, and shorter arterial trees so it takes less time to reflect systolic waves causing increased afterload 4⃣ Lung size: smaller lungs leave less functional reserve against age-related decline or respiratory disease

📊 STAREE Trial (NEJM 2026) • P: Adults age 70 without prior CVD, diabetes, or dementia (n=9,971) • I: Atorvastatin 40 mg daily • C: Placebo • O: Reduced MACE (HR 0.70), but no difference in disability-free survival or dementia (HR 0.94) Why test statins for dementia in the first place? A mechanistic roadmap: 🛡️ Protective • Prevents cerebrovascular atherosclerosis & ischemic strokes • Depletes isoprenoids in vascular & glial cells, boosting blood flow & calming oxidative stress • Reduces amyloid-β and tau protein accumulation ⚠️ Potential Harm • Depletes brain cholesterol needed for synaptic membranes & myelin • Lowers CoQ10, compromising energy production in brain cells • Depletes isoprenoids in hippocampal & cortical neurons, reversibly blunting memory consolidation & learning 💊 Molecule Matters • Lipophilic (atorvastatin, simvastatin): Readily cross the blood-brain barrier -> greater potential for direct central effects (both benefits and side effects) • Hydrophilic (rosuvastatin, pravastatin): Negligible CNS penetration -> act primarily on vascular endothelium and systemic lipids, potentially lower risk of "brain fog”

Better communication isn't just "bedside manner" - it's a CLINICAL SKILL. 5 tangible ways to improve it in the latest #JACC article: jacc.org/doi/10.1016/j.jacc.… @hmkyale

How should you adjust your exercise prescription in frail cardiac patients? Read on... @CircAHA pubmed.ncbi.nlm.nih.gov/4242…

This week, a team of researchers quietly published in @JACCJournals one of the most profound studies of valvular heart disease in recent memory. The PREVUE-VALVE study used a decentralized, in-home echocardiography model to estimate the prevalence of valvular heart disease among U.S. adults aged 65–85. Importantly, this was not a clinic-based echo cohort; participants were recruited nationally and underwent comprehensive transthoracic echo in their homes, with studies interpreted by a core lab. That intentional design choice is critical: PREVUE-VALVE is a true prevalence study, accurately representing the true burden of valve disease in the U.S. population. The findings are striking: 8.2% of older Americans have moderate or greater valvular heart disease, and 18.4% have “clinically significant” disease when mild-to-moderate regurgitation is included. TR was the most common lesion, followed by AS, MR, AR, and MS. The burden rises sharply with age, reaching nearly 15% among adults aged 80–85. Extrapolated nationally, this means approximately 4.7 million Americans aged 65–85 currently have moderate or greater VHD, projected to increase to 6.5 million by 2060. Using the broader clinically significant definition, the number is already over 10 million and projected to approach 15 million. For structural heart programs, health systems, and policymakers, the message is clear: the valve disease burden is large, growing, and will require thoughtful planning around screening, access, and treatment capacity. Congratulations to @djc795, Michael 'Mickey' Brener MD MS, and all co-authors for a stunning glimpse into the present and future of valve disease! jacc.org/doi/epdf/10.1016/j.…

CHAMPION-AF trial: LAAC vs. DOAC for AF Design: RCT multicentre international Population: N=3,000 AFib patients eligible for DOAC - 72y old - 68% male - 85% white - 69% paroxysmal - 48% ablated - CHADS-VASc 3.5 ± 1.3 Intervention group: LAAC Watchman Flx device + DOAC/ASA or DAPT x 3m then ASA indefinitely Control group: DOAC Primary outcome: CV death, CVA, or systemic embolism at 3y -> noninferior *but trend towards 17 more CVAs in device group (NNH 91) Safety outcome: Nonprocedural major bleeds at 3y -> superior Secondary outcome: All major bleeds at 3y -> noninferior Tertiary outcome: All major & clinically significant nonmajor bleeds at 3y (Fig S7) Other: No between group difference in EQ-5D or SF-12 vs. CLOSURE-AF trial: - Opposite conclusion i.e. LAAC inferior to DOAC - CLOSURE-AF population was "higher risk" - Multiple different LAAC devices vs. only 1 - DAPT post LAAC vs. mainly DOAC+ASA - Investigator led vs. industry sponsored nejm.org/doi/full/10.1056/NE…